Q2 2027
Released Nov 9, 2026, before the open
10-Q filed Nov 9, 2026, 40 days after period end · 0001764013-26-000122
What the release said
IMVT-1402 600 mg met the primary endpoint of ACR20 response at Week 28 (92.5% vs. 75.6% placebo, p=0.0139).
IMVT-1402 600 mg met the primary ACR20 endpoint at Week 28 (92.5% vs. 75.6% placebo, p=0.0139) in Period 2 of a potentially registrational trial in difficult-to-treat rheumatoid arthritis.¶2¶1
Net loss for the three months ended September 30, 2026 was $97.2 million ($0.47 per common share), compared with $126.5 million ($0.73 per common share) for the same period in 2025.¶3
Immunovant's cash and cash equivalents totaled $722.3 million as of September 30, 2026.¶4
Immunovant said it expects it is unlikely to advance IMVT-1402 further in Sjögren's disease beyond the ongoing, fully enrolled Phase 2 trial.¶5¶6
Research and development expenses were $85.0 million for the three months ended September 30, 2026, compared with $114.2 million for the three months ended September 30, 2025.¶7
- ACR20 response at Week 28, IMVT-1402 600 mg
- 92.5% vs. 75.6% placebo, p=0.0139, Period 2 of the potentially registrational D2T RA trial¶1
- Net loss, three months ended September 30, 2026
- $97.2 million $0.47 per common share; compared to $126.5 million ($0.73 per common share) for the three months ended September 30, 2025¶3
- Cash and cash equivalents
- $722.3 million As of September 30, 2026¶4
- Research and development expenses, three months ended September 30, 2026
- $85.0 million Compared to $114.2 million for the three months ended September 30, 2025¶7
- General and administrative expenses, three months ended September 30, 2026
- $19.1 million Compared to $17.5 million for the three months ended September 30, 2025¶8
- Net loss, six months ended September 30, 2026
- $250.5 million $1.22 per common share; compared to $247.1 million ($1.43 per common share) for the six months ended September 30, 2025¶9
Same quarter
| Metric | Q2 2027 | Q2 2026 | Q2 2025 | Q2 2024 |
|---|---|---|---|---|
| Net Income | -$97.25M | -$126.50M | -$109.12M | -$58.66M |
| EPS Diluted | -$0.47 | -$0.73 | -$0.74 | -$0.45 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Immunovant, Inc. · CIK 1764013 · Engraved from SEC EDGAR